Kathryn Peterson, MD
Gastroenterology · Salt Lake City, UTNPI 1225128846
Payments from drug & device makers
Across 214 payments — averaging $6297.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$570K
- Regeneron$473K
- Pfizer$111K
- Adare Pharmaceuticals, Inc.$55K
- Sanofi$35K
- Bristol Myers Squibb$34K
- plus $70K from 15 others
Across 13 payments — averaging $650.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$8K
- Sanofi$500
What the payments were for
- Consulting fees$92,35383%
- Speaking & faculty fees$11,42910%
- Travel & lodging$5,1005%
- Food & beverage$2,4362%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $570,252 |
| Regeneron | 61 | $473,062 |
| Pfizer(2 entities) | 39 | $110,858 |
| Adare Pharmaceuticals, Inc. | 15 | $54,587 |
| Sanofi | 16 | $34,772 |
| Bristol Myers Squibb | 8 | $34,059 |
| UCB Biosciences Inc. | 4 | $17,759 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $15,361 |
| E.r. Squibb & Sons, L.L.C. | 4 | $9,793 |
| Shire North American Group Inc | 8 | $5,544 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $4,750 |
| Regeneron Healthcare Solutions, Inc. | 9 | $4,066 |
| Astrazeneca UK Limited | 2 | $3,333 |
| Janssen Research & Development, LLC | 2 | $2,568 |
| Blueprint Medicines Corporation | 1 | $2,022 |
| Sanofi-aventis U.S. LLC | 2 | $1,603 |
| Eli Lilly | 2 | $1,439 |
| Lucid Diagnostics Inc. | 1 | $1,000 |
| Amgen | 1 | $723 |
| Boston Scientific | 1 | $106 |
| Phathom Pharmaceuticals, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,347,660 in reported general payments places this provider in the 95th percentile of 122 gastroenterology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 12 | $132,424 |
| Omeprazole | 23 | $518 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Salt Lake City
- John ValentineSalt Lake City$2.2M
- Priyanka KanthSalt Lake City$1.3M
- Richard GilroySalt Lake City$1.1M
- Peder PedersenSalt Lake City$1M
- Jessica JohnsonSalt Lake City$351K
- Terry BoxSalt Lake City$302K
- John FangSalt Lake City$276K
- Ashok TutejaSalt Lake City$75K
- Ann FlynnSalt Lake City$46K
- Iqbal SandhuSalt Lake City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.